Research ArticleOriginal Article
Open Access

Evaluation of the community pharmacists’ performance in the screening of non-steroidal anti-inflammatory drugs risks in Saudi Arabia

Azizah M. Malebari, Ahdab N. Khayyat, Ruba A. Mahdali, Jumana S. Alamoudi, Bushra Y. Alsayed and Samar A. Alrasheed
Saudi Medical Journal August 2020, 41 (8) 849-857; DOI: https://doi.org/10.15537/smj.2020.8.25221

References

  1. ↵
    1. Diener H-C,
    2. Schneider R,
    3. Aicher B
    (2008) Per-capita consumption of analgesics:a nine-country survey over 20 years. J Headache Pain 9:225.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Babakor SD,
    2. Al Ghamdi MM
    (2018) Prevalence and Determinants of Over-the-Counter Analgesics Usage among Patients attending Primary Health Care Centers in Jeddah, Saudi Arabia. J Young Pharm 10:91–97.
    OpenUrl
  3. ↵
    1. AlKhamees OA,
    2. AlNemer KA,
    3. Maneea MWB,
    4. AlSugair FA,
    5. AlEnizi BH,
    6. Alharf AA
    (2018) Top 10 most used drugs in the Kingdom of Saudi Arabia, 2010-2015. Saudi Pharm J 26:211–216.
    OpenUrl
  4. ↵
    1. Al Essa M,
    2. Alshehri A,
    3. Alzahrani M,
    4. Bustami R,
    5. Adnan S,
    6. Alkeraidees A,
    7. et al.
    (2019) Practices, awareness and attitudes toward self-medication of analgesics among health sciences students in Riyadh, Saudi Arabia. Saudi Pharm J 27:235–239.
    OpenUrl
  5. ↵
    1. Makeen HA,
    2. Albarraq AA,
    3. Banji OJ,
    4. Taymour S,
    5. Meraya A,
    6. Alqhatani S,
    7. et al.
    (2019) Knowledge, attitudes, and practices toward self-medication in a rural population in South-Western Saudi Arabia. Saudi J Health Sci 8:54–59.
    OpenUrl
  6. ↵
    1. Wongrakpanich S,
    2. Wongrakpanich A,
    3. Melhado K,
    4. Rangaswami J
    (2018) A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis 9:143–150.
    OpenUrlPubMed
  7. ↵
    Food and Drug Administration (FDA). Medication Guide for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Available from URLhttps://wwwfdagov/media/72932/download. [Updated 2016. Accessed 2020 January 16].
  8. ↵
    1. Bidaut-Russell M,
    2. Gabriel SE
    (2001) Adverse gastrointestinal effects of NSAIDs:consequences and costs. Best Pract Res Clin Gastroenterol 15:739–753.
    OpenUrlPubMed
  9. ↵
    1. Howard R,
    2. Avery A,
    3. Slavenburg S,
    4. Royal S,
    5. Pipe G,
    6. Lucassen P,
    7. et al.
    (2007) Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 63:136–147.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Rahme E,
    2. Joseph L,
    3. Kong SX,
    4. Watson DJ,
    5. LeLorier J
    (2000) Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen:retrospective cohort study of an elderly population. Arthritis &Rheumatology 43:917–924.
    OpenUrl
  11. ↵
    1. Davis A,
    2. John Robson
    (2016) The dangers of NSAIDs:look both ways. Br J Gen Pract 66:172–173.
    OpenUrlFREE Full Text
  12. ↵
    1. Almalak H,
    2. Albluwi AaI,
    3. Alkhelb DA,
    4. Alsaleh HM,
    5. Khan TM,
    6. Hassali MAA,
    7. et al.
    (2014) Students'attitude toward use of over the counter medicines during exams in Saudi Arabia. Saudi Pharm J 22:107–112.
    OpenUrl
  13. ↵
    1. Babelghaith SD,
    2. Alarifi MN,
    3. Wajid S,
    4. Alhawassi TM,
    5. Alqahtani SK,
    6. Alghadeer SM
    (2019) Knowledge of patients on safe medication use in relation to nonsteroidal anti-inflammatory drugs. Saudi J Anaesth 13:106–111.
    OpenUrl
  14. ↵
    1. AlRuthia Y,
    2. Alsenaidy MA,
    3. Alrabiah HK,
    4. AlMuhaisen A,
    5. Alshehri M
    (2018) The status of licensed pharmacy workforce in Saudi Arabia:a 2030 economic vision perspective. Hum Resour Health 16:28.
    OpenUrl
  15. ↵
    Ministry of Health. Statistical Yearbook, Available from URL:https://www.moh.gov.sa/Ministry/Statistics/book/Documents/book-Statistics-2018.pdf. (Updated 2018, accessed on 16 April 2019).
  16. ↵
    1. Phueanpinit P,
    2. Pongwecharak J,
    3. Krska J,
    4. Jarernsiripornkul N
    (2018) Evaluation of community pharmacists'roles in screening and communication of risks about non-steroidal anti-inflammatory drugs in Thailand. Prim Health Care Res Dev 19:598–604.
    OpenUrl
  17. ↵
    1. Jarernsiripornkul N,
    2. Phueanpinit P,
    3. Pongwecharak J,
    4. Krska J
    (2016) Experiences of and attitudes towards receiving information about non-steroidal anti-inflammatory drugs:a cross-sectional survey of patients in Thailand. Expert Opin Drug Saf 15:417–426.
    OpenUrl
  18. ↵
    1. Jarernsiripornkul N,
    2. Phueanpinit P,
    3. Pongwecharak J,
    4. Krska J
    (2019) Development and evaluation of user-tested Thai patient information leaflets for non-steroidal anti-inflammatory drugs:Effect on patients'knowledge. PloS One 14:e0210395.
    OpenUrl
    1. Karami NA,
    2. Altebainawi AF,
    3. Alfarki SA,
    4. Aldossari NB,
    5. Asiri AN,
    6. Aldahan MS,
    7. et al.
    (2018) Knowledge and attitude of analgesics use among Saudi population:A cross-sectional study. Int J Med Sci Public Health 7:137–143.
    OpenUrl
  20. ↵
    1. Abougalambou SS,
    2. Abdoun SA,
    3. SayerAlharbi N
    (2019) Awareness of non-steroidal anti-inflammatory drugs (NSAIDs) use among population in Saudi Arabia. Open J Pharm Sci Res 1:40–45.
    OpenUrl
  21. ↵
    1. Bahdailah A
    (2019) Basic knowledge of non-steroidal anti-inflammatory drugs among saudi community. PTb Reports 5:93–96.
    OpenUrl
  22. ↵
    1. Jarernsiripornkul N,
    2. Phueanpinit P,
    3. Pongwecharak J,
    4. Krska J
    (2019) Practices of healthcare professionals in communicating with nonsteroidal anti?inflammatory drug users in Thailand:a qualitative study. Int J Pharm Pract 27:326–369.
    OpenUrl
  23. ↵
    1. Alaqeel S,
    2. Abanmy NO
    (2015) Counseling practices in community pharmacies in Riyadh, Saudi Arabia:a cross-sectional study. BMC Health Serv Res 15:557.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Al-Aqeel SA
    (2012) Evaluation of medication package inserts in Saudi Arabia. Drug Healthc Patient Saf 4:33–38.
    OpenUrlPubMed
  25. ↵
    1. Chua SS,
    2. Paraidathathu T
    (2005) Utilisation of non-steroidal anti-inflammatory drugs (NSAIDs) through community pharmacies in Malaysia. Asia Pac J Public Health 17:117–123.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Puspitasari HP,
    2. Aslani P,
    3. Krass I
    (2009) A review of counseling practices on prescription medicines in community pharmacies. Research in social &administrative pharmacy. Res Social Adm Pharm 5:197–210.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Al-Mohamadi A,
    2. Badr A,
    3. Bin Mahfouz L,
    4. Samargandi D,
    5. Al Ahdal A
    (2013) Dispensing medications without prescription at Saudi community pharmacy:extent and perception. Saudi Pharm J 21:13–18.
    OpenUrl
  28. ↵
    1. Lanas A,
    2. Esplugues J-V,
    3. Zapardiel J,
    4. Sobreviela E
    (2009) Education-based approach to addressing non-evidence-based practice in preventing NSAID-associated gastrointestinal complications. World J Gastroenterol 15:5953–5939.
    OpenUrlPubMed
    1. Park K,
    2. Bavry AA
    (2014) Risk of stroke associated with nonsteroidal anti-inflammatory drugs. Vasc Health Risk Manag 10:25–32.
    OpenUrlPubMed
    1. Layton D,
    2. Souverein PC,
    3. Heerdink ER,
    4. Shakir SA,
    5. Egberts AC
    (2008) Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users:a cohort study using pharmacy dispensing data in The Netherlands. Drug Saf 31:143–158.
    OpenUrlPubMed
  31. ↵
    1. Han MH,
    2. Nam JH,
    3. Noh E,
    4. Lee EK
    (2019) Gastrointestinal risk of non-steroidal anti-inflammatory drugs and gastroprotective agents used in the treatment of osteoarthritis in elderly patients:a nationwide retrospective cohort study. Int J Clin Pharmacol Ther 57:531–541.
    OpenUrl
  32. ↵
    1. Ross SJ,
    2. Elgendy IY,
    3. Bavry AA
    (2017) Cardiovascular safety and bleeding risk associated with nonsteroidal anti-inflammatory medications in patients with cardiovascular disease. Curr Cardiol Rep 19:8.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Lanas A,
    2. Ferrandez A
    (2007) Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly. Drugs Aging 24:121–131.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Batlouni M
    (2010) Nonsteroidal anti-inflammatory drugs:cardiovascular, cerebrovascular and renal effects. Arq Bras Cardiol 94:556–563.
    OpenUrlPubMed
  35. ↵
    1. Khan S,
    2. Andrews KL,
    3. Chin-Dusting JPF
    (2019) Cyclo-oxygenase (cox) inhibitors and cardiovascular risk:are non-steroidal anti-inflammatory drugs really anti-inflammatory? Int J Mol Sci 20:4262.
    OpenUrl
  36. ↵
    1. Carrigan N,
    2. Raynor D,
    3. Knapp P
    (2008) Adequacy of patient information on adverse effects. Drug Saf 31:305–312.
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    1. Russell B,
    2. Moss C,
    3. Rigg A,
    4. Van Hemelrijck M
    (2020) COVID-19 and treatment with NSAIDs and corticosteroids:should we be limiting their use in the clinical setting? Ecancermedicalscience 14:1023.
    OpenUrlPubMed
  38. ↵
    U.S Food and Drug Administration. FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19, Available from URL:https://www.fda.gov/drugs/drug-safety-and-availability/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19. Updated 2020 February 13. Accessed 2020 April 20.
  39. ↵
    1. Al Laif FZ,
    2. Ahmad R,
    3. Naqvi AA,
    4. Ahmad N
    (2017) Pharmacist perceived barriers to patient counseling;a study in eastern region of Saudi Arabia. J Pharm Res Int 19:1–12.
    OpenUrl
    1. Asrade SA,
    2. Mishra B
    (2016) Assessment of dispensing practice and associated factors towards patient medication counseling in dessie town, north east ethiopia. Biotechnol Res Int 9:111–121.
    OpenUrl
    1. Halila GC,
    2. Junior EH,
    3. Otuki MF,
    4. Correr CJ
    (2015) The practice of OTC counseling by community pharmacists in Parana, Brazil. Pharma Prac 13:597.
    OpenUrl
  42. ↵
    1. Tarn DM,
    2. Wenger A,
    3. Good JS,
    4. Hoffing M,
    5. Scherger JE,
    6. Wenger NS
    (2015) Do physicians communicate the adverse effects of medications that older patients want to hear? Drugs Ther Perspect 3:68–76.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords